Hizentra: Proven to prevent CIDP relapse

Hizentra is the first and only subcutaneous immunoglobulin proven to prevent CIDP relapse.

People taking Hizentra:

  • Withdrew from the study or relapsed less often than those taking placebo
  • Maintained their grip strength, upper-body strength, and/or lower-body strength
Patient on CIDP – proven to prevent relapse

Real Hizentra experience in CIDP

Real Hizentra experience in CIDP

Appolos

  • Diagnosed with CIDP after a year of symptoms
  • Started Hizentra after complications with IVIg
  • Enjoying more freedom and few systemic side effects
Watch Video
Voice2Voice

To connect live with a Voice2Voice Advocate* who can answer your nonmedical questions about CIDP, call IgIQ at 1-877-355-IGIQ (4447) Mon–Fri between noon and 3 PM ET

You can also call IgIQ Mon–Fri, 8 AM–8 PM ET

*Voice2Voice advocates are not healthcare professionals or medical experts. For medical questions, please contact your physician. Voice2Voice advocates are compensated by CSL Behring LLC. for their time and/or expenses.

Demonstrated Tolerability in Clinical Trials

93% Hizentra infusions with no side effects

of Hizentra infusions were completed without any reported side effects

fewer systemic side effects

In clinical trials, patients experienced fewer systemic side effects per infusion (like headache and nausea) with Hizentra than with IVIg

In clinical trials for Hizentra, the most common side effects were redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting.

You are now leaving the current website.

Do you want to continue?

No Yes